JNMT
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow CME Activity
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cole, W. C.
Right arrow Articles by Bloodworth, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cole, W. C.
Right arrow Articles by Bloodworth, G.
Journal of Nuclear Medicine Technology Volume 34, Number 2, 2006 67-73
© 2006 by Society of Nuclear Medicine

Essential Role of Nuclear Medicine Technology in Tositumomab and 131I-Tositumomab Therapeutic Regimen for Non-Hodgkin's Lymphoma*

William C. Cole1, Jennifer Barrickman, CNMT2 and Glen Bloodworth, CNMT2

1 University of Colorado Health Sciences Center, Denver, Colorado; and 2 GlaxoSmithKline Oncology, Research Triangle Park, North Carolina

Correspondence: For correspondence or reprints contact: Glen Bloodworth, CNMT, GlaxoSmithKline Oncology, 229 White Oak Dr., Wilmington, NC 28409. E-mail: glen.a.bloodworth{at}gsk.com

ABSTRACT

Nuclear medicine technology has traditionally focused on diagnostic imaging, with therapeutics left mostly to other medical disciplines. However, after many years in development, radioimmunotherapy (RIT) has finally become a clinical reality in many nuclear medicine departments. The nuclear medicine technologist is a key player in the successful implementation of RIT. Delivery of a therapeutic regimen of tositumomab and 131I-tositumomab provides a model for the technologist's roles and responsibilities in the developing field of RIT. This article examines the clinical rationale, logistic requirements, and imaging and dosimetry procedures required by this treatment regimen. Upon completion of this article, the reader should be able to describe the target patient population and identify the roles and responsibilities of various members of the treatment team. The reader will also gain an understanding of the treatment process, including drug administration, imaging, and therapeutic dose calculations.

Key Words: non-Hodgkin's lymphoma; radioimmunotherapy






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE JOURNAL OF NUCLEAR MEDICINE JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY
Copyright © 2006 by the Society of Nuclear Medicine Technologist Section.